Skip to main content

RT @drdavidliew: There will be plenty of debate about ORAL Surveillance, as there should be. We will see more granular d

Social Author Name
David Liew
Tweet Content
There will be plenty of debate about ORAL Surveillance, as there should be. We will see more granular data, as we should. Whatever the case, it's hard to argue that there's no cancer risk with tofacitinib vs TNFi in RA, at least for some patients at higher risk. #ACR21 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×